Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Last trade$156.94
Day change-$2.79 (-1.75%)
Day range$155.85 – $161.15
Volume1,129,195
Market cap$21.39B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$21.39B
Price / earnings
7.85×
Price / book
5.94×
Price / sales
4.27×
EV / sales
4.12×
EV / EBITDA
19.99×
Profitability
Earnings per share
$20.34
Return on assets
34.08%
Return on equity
75.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.28×
Current ratio
2.48×
Quick ratio
2.43×
Cash ratio
0.85×
Cash flow
Price / cash flow
23.72×
Price / free cash flow
28.44×
Free cash flow
$752.13M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALNY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.46B
$1.29B
$1.17B
$1.1B
$1.25B
$773.69M
$594.19M
$593.17M
Cost of revenue
$361.75M
$298.26M
$207.52M
$267.72M
$197.23M
$142.03M
$70.18M
$102.65M
Gross profit
$1.1B
$992.69M
$959.66M
$829.31M
$1.05B
$631.66M
$524.01M
$490.52M
Selling, general and administrative
$342M
$347.92M
$322.55M
$325.37M
$322.08M
$323.31M
$239.95M
$295.34M
Research and development
$408.54M
$413.13M
$364.87M
$372.22M
$358.81M
$323.62M
$265.12M
$300.17M
Total operating expenses
$750.54M
$761.25M
$691.02M
$697.59M
$683.81M
$647.86M
$505.93M
$595.68M
Operating income
$345.8M
$231.44M
$268.64M
$131.72M
$367.98M
-$16.2M
$18.08M
-$105.16M
Interest expense
-$84.37M
-$82.05M
-$69.29M
-$129.34M
-$67.46M
-$61.46M
-$58.31M
-$38.97M
Income before taxes
$295.81M
$177.81M
$221.65M
$161.14M
$280.57M
-$41.31M
-$2.37M
-$193.96M
Income taxes
-$1.87B
$13.31M
$15.66M
-$25.28M
-$12.12M
$30.92M
$15.88M
-$110.2M
Net income
$2.17B
$164.49M
$205.99M
$186.42M
$292.68M
-$72.23M
-$18.25M
-$83.76M
Net income attributable to common shareholders
$2.17B
$164.49M
$205.99M
$186.42M
$292.68M
-$72.23M
-$18.25M
-$83.76M
EBITDA
$360.27M
$245.34M
$282.19M
$145.22M
$381.79M
-$2.26M
$32.48M
-$90.99M
Basic earnings per share
$16.19
$1.23
$1.55
$1.41
$2.23
-$0.55
-$0.14
-$0.65
Diluted earnings per share
$15.72
$1.21
$1.51
$1.32
$2.14
-$0.55
-$0.14
-$0.65
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's October 29, 2026 earnings report. Alnylam reported significant slowing in demand for its key drug Amvuttra, which represents 87.5% of product sales, with U.S. transthyretin demand declining from $129 million to $81 million quarter-over-quarter. The announcement triggered a sharp 25.13% stock price decline.
DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.
Wall Street analysts identify three Nasdaq-100 stocks with potential to double based on median target prices: CoreWeave (140% upside) as a leading AI cloud provider with strong revenue growth but profitability concerns due to high debt; Nebius Group (100% upside) as an emerging AI cloud competitor with faster revenue growth but expensive valuation; and Alnylam Pharmaceuticals (100% upside) as an RNA interference therapy leader with an attractive valuation and promising pipeline.
Alnylam Pharmaceuticals reported quarterly earnings of $16.26 per share, significantly beating the consensus estimate of $2.19, with revenues of $1.46 billion. However, the stock has underperformed the market by 41.6% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. Alkermes is expected to report a quarterly loss of $0.08 per share with revenues projected at $465.92 million.
Krystal Biotech is expected to report a 30.8% year-over-year decline in earnings per share to $1.84 for Q3 2026, despite revenues rising 27.5% to $124.65 million. With a Zacks Rank of #5 (Strong Sell) and a modest positive Earnings ESP of +1.50%, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten consensus estimates in four of the last four quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.